Coding

Part:BBa_K5211014:Design

Designed by: Niexin Zhou   Group: iGEM24_CHINA-HUBU-WUHAN   (2024-09-30)


The GCG gene, fully known as the proglucagon gene, is a crucial gene encoding multiple hormone precu


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Design Notes

The GCG gene, fully known as the proglucagon gene, is a crucial gene encoding multiple hormone precursors in the human body and can code for the GLP-1 protein. GLP-1, in its full term Glucagon-like Peptide-1, is a hormone secreted by L cells in the intestine. It plays a vital role in regulating blood glucose levels by promoting insulin secretion and inhibiting glucagon release. This effect is dependent on variations in blood glucose levels, exerting its function when blood glucose is elevated but not further lowering blood glucose when it is normal, thereby reducing the risk of hypoglycemia. Furthermore, GLP-1 can also delay gastric emptying, enhance satiety, and reduce food intake. These characteristics render it highly effective in the treatment of type 2 diabetes and obesity. In recent years, the development of GLP-1 receptor agonists has offered new therapeutic choices for patients with diabetes and paved new paths for the treatment of obesity.


Source

The GCG gene, fully known as the proglucagon gene, is a crucial gene encoding multiple hormone precursors in the human body and can code for the GLP-1 protein. GLP-1, in its full term Glucagon-like Peptide-1, is a hormone secreted by L cells in the intestine. It plays a vital role in regulating blood glucose levels by promoting insulin secretion and inhibiting glucagon release. This effect is dependent on variations in blood glucose levels, exerting its function when blood glucose is elevated but not further lowering blood glucose when it is normal, thereby reducing the risk of hypoglycemia. Furthermore, GLP-1 can also delay gastric emptying, enhance satiety, and reduce food intake. These characteristics render it highly effective in the treatment of type 2 diabetes and obesity. In recent years, the development of GLP-1 receptor agonists has offered new therapeutic choices for patients with diabetes and paved new paths for the treatment of obesity.

References